SCHEMBL1490905

SCHEMBL1490905

O=C1CCN(C(=O)c2ccc(B(O)O)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.48
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GPR183 P32249 1/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL3 Q96JM7 2/20 0.40
POLB P06746 1/20 0.40
MLYCD O95822 1/20 0.40
PHGDH O43175 1/20 0.40
MBTD1 Q05BQ5 1/20 0.40
TP53BP1 Q12888 1/20 0.40
L3MBTL4 Q8NA19 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29950978 0.87 HPGD (0.57) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL24120195 0.87 HPGD (0.61) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL950365 0.84 HPGD (0.64) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL204078 0.84 HPGD (0.70) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL258027 0.82 HPGD (0.74) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL13022078 0.81 GPR183 (0.54) HPGDALDH1A1LMNASMN1; SMN2GPR183
SCHEMBL27811868 0.80 HPGD (0.53) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL2987838 0.80 MTHFD2 (0.54) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL1951522 0.79 SIGMAR1 (0.64) HPGDALDH1A1L3MBTL3L3MBTL1
SCHEMBL29956781 0.79 HPGD (0.65) HPGDALDH1A1LMNAGPR183MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897609-B2 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
WO-2009150144-A1 NEW GPR119MODULATORS INOVACIA AB (SE) 2009-12-17 WO disclosed
US-20070259907-A1 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2007-11-08 US disclosed
US-20070219228-A1 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259907-A1 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES IL2, TSLP, IFNG HPGD 773/4885ALDH1A1 521/4885LMNA 4785/4885
US-20070219228-A1 Aryl substituted imidazonaphthyridines IL2, IRF3, EIF2AK2 HPGD 449/4885ALDH1A1 1178/4885LMNA 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.